Versiti Clinical Trials Services partners with 4D Path to accelerate personalized cancer treatment development. April 21, 2026. The AI-driven platform delivers tumor treatment predictive biomarkers to oncology researchers faster, more accurately, and at scale. MILWAUKEE and NEWTON, MA - April 21, 2026 - Versiti Clinical Trials Services (VCTS) has launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments. The collaboration makes 4D Path's Q-Plasia OncoReader (QPOR(TM) platform available to pharmaceutical companies and clinical research organizations working with VCTS, giving them powerful new tools to understand how individual cancers respond to treatment. QPOR(TM) transforms routine biopsy images into clear treatment predictive biomarkers that reveal how tumors and immune systems interact. The physics-inspired, AI-driven deterministic platform delivers these insights faster and at lower cost than traditional methods, helping researchers make critical decisions earlier in the development process. The QPOR(TM) platform is available to VCTS clients immediately. "Every day matters when we're developing treatments that could save lives," Chris Miskel, President and CEO of Versiti, says. "This partnership gives our clients the speed and precision they need to bring personalized cancer therapies to patients who can no longer wait. We're seeing a deeper understanding of how individual cancers behave, with unprecedented clarity that wasn't possible before." The QPOR(TM) platform works across cancers, providing robust, consistent, and reproducible results that meet regulatory standards. Clinical trial sponsors gain biologically explainable, treatment predictive insights that speed decision-making while reducing costs. For patients, this means potentially faster access to treatments tailored to their specific cancer. "VCTS shares our commitment to making precision medicine accessible and practical," said Tathagata Dasgupta, founder, president, and CTO of 4D Path. "Together, we're giving researchers the clarity and insights they need to develop better treatments faster, without special processing or added complexity." The partnership strengthens VCTS's position as a leader in oncology clinical trials, offering clients a comprehensive platform that combines proven trial management expertise with breakthrough analytical capabilities. About Versiti Clinical Trials Services Versiti Clinical Trials Services, a division of Versiti Blood Health, Inc., is dedicated to advancing life sciences research and improving patient outcomes through innovative clinical study support services. 4D Path Inc. collaborate with healthcare professionals, research institutions, and industry partners to develop life-changing solutions. Its commitment to scientific excellence, patient-centered care, and ethical research practices drives 4D Path Inc. to explore groundbreaking solutions for a healthier future. About 4D Path 4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR(TM), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient's response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications - bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life. For additional information, please visit www.4dpath.com or follow 4D Path on LinkedIn. (617) 558-0010 Versiti PR Contact Kristin Paltzer Senior Manager Media and Public Relations [email protected] (414) 937-6143

Aspire North community blood drive. 03.20.2026 By Heather Sauer On Friday, March 20th, Aspire North Realtors proudly hosted a community blood drive from 11:00 AM - 3:30 PM, bringing members and community supporters together for an important cause, helping save lives through blood donation. Its goal for the day was to collect 15 units of whole blood, and thanks to the generosity of its community, Aspire North REALTORS were able come extremely close to that with 14 units of whole blood collected. Every donation has the potential to help multiple patients, making a meaningful impact for individuals and families in need. This blood drive would not have been possible without the support of Versiti, who partnered with Aspire North Realtors to organize and facilitate the event. Their team ensured the process was smooth, safe, and welcoming for all donors. Aspire North REALTORS would also like to extend a heartfelt thank you to everyone who volunteered their time to donate. Your willingness to give back demonstrates the strong sense of community that makes Aspire North Realtors such a special organization. Whether you were a first-time donor or a returning one, your contribution truly matters. Events like this remind Aspire North REALTORS that small acts of generosity can have a powerful impact. Aspire North Realtors is proud to support initiatives that strengthen its community and help those in need. Aspire North REALTORS look forward to continuing opportunities like this in the future and hope even more members will join Aspire North REALTORS next time to help make an even greater difference. Heather Sauer Heather Sauer is the Human Resource Manager for Aspire North Realtors, bringing a strong background in human resources, leadership, and business strategy. She began her career in retail management while earning her Bachelor's degree in Business Administration from Northwood University, later transitioning into human resources at Target, where she served as an Executive Team Leader of Human Resources. During this time, she earned her MBA from the Northwood University DeVos Graduate School. After relocating to Traverse City, Michigan, Heather continued her HR career with a Professional Employer Organization (PEO), managing more than 30 client accounts and partnering closely with leadership teams on employee relations, compliance, and organizational development. In the fall of 2023, she expanded her professional experience into business development and entrepreneurship. In addition to her role at Aspire North Realtors, Heather is also an independent travel agent, helping individuals, families, and groups plan seamless, memorable travel experiences. Her passion for service, organization, and relationship-building carries through both her HR and travel work.

MACC Fund commits $11.5 million to propel pediatric cancer research at Versiti Blood Research Institute. PR Newswire Today at 8:03am PST PR Newswire MILWAUKEE, March 3, 2026 MILWAUKEE, March 3, 2026 /PRNewswire/ - The MACC Fund has committed $11.5 million to advance pediatric cancer research at the Versiti Blood Research Institute, strengthening a long-standing partnership dedicated to improving outcomes for children facing leukemia and other blood disorders. "The MACC Fund is proud to partner with the Versiti Blood Research Institute to spotlight and accelerate Versiti's pioneering work in leukemia biology, immune discovery, and translational research. Kids deserve better treatment options. Kids deserve to be kids. By expanding our support, we're empowering researchers to move discoveries from the lab to life-changing treatments, faster, smarter, and with renewed hope for every child to thrive," said Becky Pinter, president and CEO of the MACC Fund. The multiyear investment will accelerate high-impact research already underway in pediatric leukemia biology, immune system discovery and translational science that moves insights from the lab toward the bedside. The commitment will support investigator recruitment and retention, expand translational research capacity, advance active clinical and laboratory studies, and provide sustained funding to pursue emerging scientific opportunities in pediatric leukemia. There are two primary types of pediatric leukemia: acute lymphoblastic leukemia, or ALL, and the rarer acute myeloid leukemia, or AML. ALL is the most common cancer among children, with more than 3,000 new cases diagnosed annually in the United States. While survival rates for ALL are approximately 90 percent, AML remains devastating, with nearly half of diagnosed children dying from the disease. Versiti researchers are working to change that trajectory. Current areas of study include: * Developing next-generation precision oncology immunotherapies * Using CAR T-cell therapy to train patients' immune systems to fight cancer * Building a basic understanding and clinical use of natural killer cells * Reducing toxicity in existing treatments * Applying artificial intelligence to bioinformatics to create more targeted, precise therapies Versiti currently has four faculty-level investigators leading pediatric leukemia research projects, with plans to add one to two more in the next 12 months. The institute is conducting two active clinical and translational studies and six active scientific studies, supported by 20 research staff members. In the past two years alone, investigators have published 54 peer-reviewed publications. The multiyear investment will accelerate high-impact research already underway in pediatric leukemia biology, immune system discovery and translational science that moves insights from the lab toward the bedside. The commitment will support investigator recruitment and retention, expand translational research capacity, advance active clinical and laboratory studies, and provide sustained funding to pursue emerging scientific opportunities in pediatric leukemia. This expanded capacity aligns with the 79,000-square-foot Versiti Blood Research Institute expansion, providing the space and infrastructure to scale collaboration, equipment, and pilot projects that will translate discoveries into next-generation therapies for children. The expansion is on track to be completed and open to researchers in late 2026. "When a community chooses to invest in research, it invests in a child's future. The MACC Fund's bold $11.5 million commitment will fuel leading-edge scientific work at Versiti that has the potential to change outcomes for children facing cancer. We are grateful for this partnership and committed to delivering breakthrough discoveries for families in need," said Chris Miskel, president and CEO of Versiti. The MACC Fund has long mobilized community support to fuel childhood cancer research. This investment reflects a shared commitment to strengthening scientific capacity, supporting leading investigators, and sustaining discovery that improves survival rates while reducing treatment toxicity for children. This partnership underscores Milwaukee's leadership in pediatric cancer research while contributing to discoveries that have the potential to impact children nationwide. About the MACC Fund The MACC Fund (Midwest Athletes Against Childhood Cancer, Inc.) is a non-profit founded in 1976 with a mission to fund a cure for childhood cancer and related blood disorders by providing funding for research. Over the years, the MACC Fund has contributed nearly $90 million toward groundbreaking research in these areas. In addition to funding research, the MACC Fund raises awareness and engages the community to bring hope to children and families. About Versiti Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of healthcare partners nationally. The organization is a 501(c)(3) not-for-profit headquartered in Milwaukee, with more than 2,700 employees at locations in Illinois, Indiana, Michigan, Ohio, Texas and Wisconsin. Versiti provides innovative, value-added solutions in transfusion medicine, transplantation, and blood-related diseases to meet the needs of its customers. The collective efforts result in improved patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide. For more information, visit Versiti.org. SOURCE Versiti, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.